XML 57 R34.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Selected Quarterly Financial Data (unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract] |
Selected Quarterly Financial Data (unaudited) | Selected quarterly financial data (unaudited)
2018 | December 31 |  | September 30 |  | June 30 |  | March 31
Total revenues | $ | 2,821,124 |  |  | $ | 2,847,330 |  |  | $ | 2,886,953 |  |  | $ | 2,849,444 |
Operating income | $ | 387,908 |  |  | $ | 289,038 |  |  | $ | 438,192 |  |  | $ | 410,686 |
Attributable to DaVita Inc.: |  |  |  |  |  |  |
Net income from continuing operations(1) | $ | 160,332 |  |  | $ | 73,371 |  |  | $ | 199,603 |  |  | $ | 191,015 |
Net (loss) income from discontinued operations(2) | $ | (310,104 | ) |  | $ | (210,167 | ) |  | $ | 67,673 |  |  | $ | (12,329 | )
Net (loss) income | $ | (149,772 | ) |  | $ | (136,796 | ) |  | $ | 267,276 |  |  | $ | 178,686 |
Per share attributable to DaVita Inc.: |  |  |  |  |  |  |
Basic net income from continuing operations | $ | 0.97 |  |  | $ | 0.44 |  |  | $ | 1.16 |  |  | $ | 1.07 |
Basic net (loss) income from discontinued operations | $ | (1.87 | ) |  | $ | (1.26 | ) |  | $ | 0.40 |  |  | $ | (0.07 | )
Basic net (loss) income | $ | (0.90 | ) |  | $ | (0.82 | ) |  | $ | 1.56 |  |  | $ | 1.00 |
Diluted net income from continuing operations | $ | 0.96 |  |  | $ | 0.44 |  |  | $ | 1.15 |  |  | $ | 1.05 |
Diluted net (loss) income from discontinued operations | $ | (1.86 | ) |  | $ | (1.26 | ) |  | $ | 0.38 |  |  | $ | (0.07 | )
Diluted net (loss) income | $ | (0.90 | ) |  | $ | (0.82 | ) |  | $ | 1.53 |  |  | $ | 0.98 |
2017 |  |  |  |  |  |  |
Total revenues | $ | 2,780,913 |  |  | $ | 2,765,071 |  |  | $ | 2,699,399 |  |  | $ | 2,631,251 |
Operating income | $ | 150,337 |  |  | $ | 395,294 |  |  | $ | 391,196 |  |  | $ | 875,928 |
Attributable to DaVita Inc.: |  |  |  |  |  |  |
Net income from continuing operations(1) | $ | 156,210 |  |  | $ | 152,870 |  |  | $ | 151,292 |  |  | $ | 440,905 |
Net income (loss) from discontinued operations(2) | $ | 147,186 |  |  | $ | (367,346 | ) |  | $ | (24,291 | ) |  | $ | 6,792 |
Net income (loss) | $ | 303,396 |  |  | $ | (214,476 | ) |  | $ | 127,001 |  |  | $ | 447,697 |
Per share attributable to DaVita Inc.: |  |  |  |  |  |  |
Basic net income from continuing operations | $ | 0.86 |  |  | $ | 0.81 |  |  | $ | 0.79 |  |  | $ | 2.29 |
Basic net income (loss) from discontinued operations | $ | 0.80 |  |  | $ | (1.95 | ) |  | $ | (0.13 | ) |  | $ | 0.04 |
Basic net income (loss) | $ | 1.66 |  |  | $ | (1.14 | ) |  | $ | 0.66 |  |  | $ | 2.33 |
Diluted net income from continuing operations | $ | 0.85 |  |  | $ | 0.80 |  |  | $ | 0.78 |  |  | $ | 2.26 |
Diluted net income (loss) from discontinued operations | $ | 0.79 |  |  | $ | (1.92 | ) |  | $ | (0.13 | ) |  | $ | 0.03 |
Diluted net income (loss) | $ | 1.64 |  |  | $ | (1.12 | ) |  | $ | 0.65 |  |  | $ | 2.29 |
(1) | Included in the fourth quarter of 2018 is a net gain on changes in ownership interests of $28,152; an equity investment loss of $8,715 due to the sale of the APAC JV's India business; and an equity investment loss of $1,530 due to impairments at the APAC JV. The third quarter of 2018 includes restructuring charges of $11,366 and other asset impairment charges of $6,093 related to the Company's pharmacy business; an equity investment loss of $5,995 due to impairments at the APAC JV; an adjustment to the gain on changes in ownership interests on the sale of the Company's direct primary care business of $1,506; and $23,470 in additional stock-based compensation expense related to modification charges and net acceleration of expense. The second quarter of 2018 includes asset impairment charges of $11,245 related to the pharmacy business; a net gain on changes in ownership interests of $35,205 on the Company's direct primary care business; a loss of $1,248 related to the unwinding of a business internationally; and a goodwill impairment charge of $3,106 at the Company's German other health operations. Included in the fourth quarter of 2017 was an impairment of $280,066 on the Company's investment in the APAC JV. The third quarter of 2017 included an equity investment loss of $6,293 for goodwill impairments at the APAC JV and restructuring charges in the Company's international business of $2,700. The second quarter of 2017 included goodwill impairment charges of $10,498 related to the vascular access reporting unit. The first quarter of 2017 included a net gain on settlement of $529,504; goodwill impairment charges of $24,198 related to the vascular access reporting unit; an asset impairment of $15,168 related to the restructuring of the pharmacy business; and a gain adjustment on the 2016 ownership change of the APAC JV of $6,273.
(2) Included in discontinued operations in the fourth quarter of 2018 is a $218,639 disposal group valuation adjustment, a $41,537 goodwill impairment charge and $8,318 in related tax benefit. The third quarter of 2018 includes a $216,147 charge on the Company's DMG business which included a $98,201 disposal group valuation adjustment and $117,946 in related tax expense on this held-for-sale business. The second quarter of 2018 includes a gain on the sale of the Company's Tandigm investment of $25,096. The fourth quarter of 2017 includes a net tax benefit of $163,555 due to a remeasurement of deferred taxes resulting from DMG's reclassification to held for sale. The third quarter of 2017 includes goodwill impairment charges of $601,040 related to certain DMG reporting units; a non-cash gain associated with the Company's Magan acquisition of $17,129; restructuring charges of $9,569; and a reduction in estimated accruals for legal matters of $11,100. The second quarter of 2017 includes goodwill impairment charges of $50,619 related to certain DMG reporting units and a reduction in estimated accruals for legal matters of $3,600.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration